Annovis Bio earnings release, August 14, 2026

Annovis Bio, Inc. (ANVS) · Form 8-K, Item 2.02 · Filed · SEC filing

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

Malvern, PA, August 14, 2026 -- Annovis Bio, Inc. (NYSE:

ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the second quarter ended June 30, 2026.

“Our company witnessed major clinical strides during the second quarter,” said Maria Maccecchini, Ph.D., President and CEO of Annovis. “We reached an important milestone – full enrollment of our pivotal Phase 3 study in early AD – having recruited 850 patients. This number tells us how urgently patients and families need new options and underscores their faith in our approach to treating AD. We also plan to continue the ongoing study with an open-label extension (OLE) so AD patients can continue buntanetap treatment after finishing the trial. With topline data on track for early 2027, our team has already begun preparing for regulatory submission so that we are ready to move once the results are in hand.”

Clinical highlights

Alzheimer’s disease – pivotal Phase 3 trial

Alzheimer’s disease – OLE study

Parkinson’s disease – OLE study

Corporate highlights

Upcoming milestones

Financial results

About

Annovis

Headquartered in Malvern, Pennsylvania, Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The Company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. For more information, visit www.annovisbio.com and follow us on

LinkedIn, YouTube, and

X.

Investor

Alerts

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended — ANNOVIS BIO, INC. Statement of Operations (Unaudited)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Operating expenses:Research and development12,007,3005,161,92128,727,66310,173,438
Operating expenses:General and administrative2,370,4121,109,5323,662,2322,380,696
Operating expenses:Total operating expenses14,377,7126,271,45332,389,89512,554,134
Operating expenses:Operating loss-14,377,712-6,271,453-32,389,895-12,554,134
Other income:Interest income160,233191,395298,033379,007
Other income:Other financing costs (Note 7)-1,589,336-1,589,336
Other income:Change in fair value of warrants (Note 7)986,000-140,0001,254,000418,000
Other income:Total other income, net-443,10351,395-37,303797,007
Other income:Net loss-14,820,815-6,220,058-32,427,198-11,757,127
Net loss per share (Note 9)Basic-0.4-0.32-0.99-0.64
Net loss per share (Note 9)Diluted-0.4-0.32-0.99-0.64
Weighted-average number of common shares used in computing net loss per shareBasic37,518,77819,486,23132,710,04618,464,877
Weighted-average number of common shares used in computing net loss per shareDiluted37,518,77819,486,23132,710,04618,464,877

Balance Sheet

ANNOVIS BIO, INC. Balance Sheets

June 30, – 2026 – (Unaudited)December 31, – 2025
Current assets:Cash and cash equivalents18,728,94519,532,338
Current assets:Prepaid expenses and other current assets3,308,1461,549,287
Current assets:Total assets22,037,09121,081,625
Current liabilities:Accounts payable3,327,1382,590,516
Current liabilities:Accrued expenses3,031,5721,044,859
Current liabilities:Total current liabilities6,358,7103,635,375
Non-current liabilities:Warrant liability19,933,000595,000
Non-current liabilities:Total liabilities26,291,7104,230,375
Stockholders’ equity:Common stock - $0.0001 par value, 70,000,000 shares authorized, 42,606,152 and 27,199,139 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively4,2602,719
Stockholders’ equity:Additional paid-in capital191,871,978180,552,190
Stockholders’ equity:Accumulated deficit-196,130,857-163,703,659
Stockholders’ equity:Total stockholders’ equity-4,254,61916,851,250
Stockholders’ equity:Total liabilities and stockholders’ equity22,037,09121,081,625
Full release

This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange

Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s

SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.

Contact

Information:

Annovis Bio Inc.

101 Lindenwood Drive

Suite 225

Malvern, PA 19355 www.annovisbio.com

Investor

Contact:

Alexander Morin, Ph.D.

Director, Strategic Communications

Annovis Bio ir@annovisbio.com

(Tables to follow)

ANNOVIS BIO, INC.

Balance Sheets

ANNOVIS BIO, INC.

Statement of Operations

(Unaudited)

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.